Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.vaishalipharma.com | |
Market Cap | 149.41 Cr. | |
Enterprise Value(EV) | 162.77 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 6.03 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 23.39 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 38.71 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 34.27 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 4.11 | Calculated using Price: 141.00 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 1.06 Cr. | 10,596,213 Shares |
FaceValue | 10 | |
About Vaishali Pharma Ltd. | ||
The company is a pharmaceutical company, dealing in pharmaceutical formulations, APIs, surgical products, veterinary supplements. It is operating both in domestic and export markets. In domestic markets, it is majorly into trading of APIs whereas in export markets, it is into trading and marketing of APIs, formulations, surgical products and others. For its export markets, the company gets the formulations manufactured by third parties whose facilities are approved and certified by the respective countries for developing the respective products. At present, it has applied for 186 registrations in 13 countries for some of its products, out of which it has successfully received 71 approvals from 7 countries and is in process of obtaining remaining approvals, which will give boost to its export business operations. |
1 Day |
|
+5.65% |
1 Week |
|
+4.46% |
1 Month |
|
+7.83% |
3 Month |
|
+17.23% |
6 Month |
|
+14.96% |
1 Year |
|
+19.97% |
2 Year |
|
+343.22% |
5 Year |
|
+394.68% |
10 Year |
|
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | 5.12 | -0.94 | 19.80 | 6.49 | 3.40 | 0.15 | 4.78 | 16.50 | 22.26 | |
Return on Capital Employed (%) | 14.04 | 12.80 | 16.18 | 12.75 | 9.80 | 6.89 | 10.33 | 18.87 | 21.92 | |
Return on Assets (%) | 0.33 | -0.06 | 1.51 | 1.47 | 1.08 | 0.05 | 1.38 | 4.81 | 8.24 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 3 | 3 | 4 | 21 | 21 | 21 | 22 | 26 | 41 | 44 | |
Non Curr. Liab. | 8 | 5 | 3 | 3 | 5 | 4 | 4 | 3 | 6 | 5 | |
Curr. Liab. | 34 | 42 | 37 | 41 | 42 | 40 | 59 | 52 | 32 | 31 | |
Minority Int. | |||||||||||
Equity & Liab. | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 81 | 79 | 80 | |
Non Curr. Assets | 2 | 2 | 5 | 5 | 6 | 5 | 5 | 5 | 6 | 6 | |
Curr. Assets | 44 | 47 | 40 | 59 | 63 | 61 | 81 | 76 | 73 | 74 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 46 | 49 | 45 | 64 | 69 | 66 | 86 | 81 | 79 | 80 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 95 | 67 | 64 | 68 | 75 | 60 | 54 | 76 | 70 | 72 | |
Other Income | 4 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 2 | 2 | |
Total Income | 99 | 70 | 65 | 69 | 77 | 62 | 56 | 78 | 72 | 74 | |
Total Expenditure | -95 | -66 | -61 | -65 | -73 | -59 | -51 | -69 | -60 | -63 | |
PBIDT | 4 | 4 | 4 | 4 | 4 | 3 | 4 | 9 | 12 | 11 | |
Interest | -3 | -3 | -3 | -3 | -3 | -3 | -3 | -2 | -2 | -2 | |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -1 | -1 | |
Taxation | 0 | 0 | 0 | -1 | 0 | 0 | 0 | -2 | -2 | -2 | |
Exceptional Items | |||||||||||
PAT | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 7 | 6 | |
Adjusted EPS | 2 | 0 | 1 | 1 | 1 | 0 | 1 | 4 | 6 | 6 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | -7 | -4 | 5 | 0 | -9 | 4 | 3 | 2 | 1 | 1 | |
Cash Fr. Inv. | 0 | 2 | 3 | 1 | 1 | 0 | 0 | 0 | -1 | 0 | |
Cash Fr. Finan. | 6 | 2 | -8 | -1 | 9 | -4 | -3 | -2 | 0 | -2 | |
Net Change | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | ||
Cash & Cash Eqvt | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
Thu, 30 Nov 2023
Analysts/Institutional Investor Meet/Con. Call Updates
|
|
Wed, 29 Nov 2023
Press Release
|
|
Wed, 29 Nov 2023
Investor Presentation
|
Tue, 05 Dec 2023 |
|
|
|
|
|